EUVIMEDEUVIMED entdecken
Crossref

Atrial Fibrillation in Advanced Chronic Kidney Disease: A Survey of Current Management in Australia and New Zealand

Mandy M Law iD, Sven-Jean Tan, Michael C G Wong, Nigel D Toussaint iD

Nephrology · 2025

DOI: 10.1111/nep.14422 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nephrology, 2025. Verfasst von Mandy M Law und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, the Royal Melbourne Hospital, Parkville, Victoria, Australia. Hauptthemen laut MEDLINE: Atrial Fibrillation, Renal Insufficiency, Chronic, Nephrologists, Cardiologists. Die Arbeit nennt 32 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

There is limited evidence to support the use of oral anticoagulation (OAC) in people with advanced chronic kidney disease (CKD) and atrial fibrillation (AF). The aim of this study is to characterise the practice patterns and priorities of clinicians in the management of non‐valvular AF and primary prevention of AF‐related stroke in people with stage 4‐5D CKD.

Methods

This was an annonymous, multiple‐choice, electronic survey distributed to and undertaken by nephrology and cardiology clinicians in Australia and New Zealand.

Results

Responses eligible for analysis were received from 181 clinicians (121 nephrology and 60 cardiology respondents). Management with close specialty collaboration was reported by 47% of all respondents. OAC use was predominantly based on estimated individual stroke risk (i.e., CHA 2 DS 2 ‐VASc score) in people with stage 4 CKD and kidney transplant recipients. In stage 5/5D CKD, nephrology respondents were more likely to withhold all antithrombotic therapy or individualise OAC use ( p < 0.05), whilst cardiology respondents were more likely to defer OAC decision‐making to another specialist ( p < 0.01). Varied use and dosing of OAC agents were noted between specialties. Left atrial appendage occlusion experience was limited amongst nephrology respondents but cardiology respondents would consider in individualised cases. Impact of CKD severity was noted in some rate and/or rhythm control management decisions.

Conclusions

This survey provides important contemporary insights into the management of AF in people with advanced CKD in Australia and New Zealand. There was inter‐ and intra‐specialty heterogeneity in practice, highlighting the need for multidisciplinary care and research to improve cardiovascular outcomes in this population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Atrial FibrillationRenal Insufficiency, ChronicNephrologistsCardiologistsPractice Patterns, Physicians'StrokeAustraliaNew ZealandAnticoagulantsSurveys and QuestionnairesPatient Care TeamKidney Function TestsRisk AssessmentHumans

Stichwörter der Autor:innen

cardiovascular diseasechronic kidney disease (CKD)haemodialysisperitoneal dialysis

Substanzen

Anticoagulants

Autor:innen und Institutionen

  • Department of Nephrology, the Royal Melbourne Hospital, Parkville, Victoria, Australia.
  • Department of Medicine, University of Melbourne, Parkville, Victoria, Australia.
  • Department of Cardiology, the Royal Melbourne Hospital, Parkville, Victoria, Australia.

ORCID-Profile: Mandy M Law, Nigel D Toussaint

Zitieren

APA

Law, M. M., Tan, S. J., Wong, M. C. G., & Toussaint, N. D. (2025). Atrial Fibrillation in Advanced Chronic Kidney Disease: A Survey of Current Management in Australia and New Zealand. Nephrology. https://doi.org/10.1111/nep.14422

Vancouver

Law MM, Tan SJ, Wong MCG, Toussaint ND. Atrial Fibrillation in Advanced Chronic Kidney Disease: A Survey of Current Management in Australia and New Zealand. Nephrology. 2025. doi:10.1111/nep.14422

BibTeX
@article{Law2025,
  author = {Law, Mandy M and Tan, Sven-Jean and Wong, Michael C G and Toussaint, Nigel D},
  title = {Atrial Fibrillation in Advanced Chronic Kidney Disease: A Survey of Current Management in Australia and New Zealand},
  journal = {Nephrology},
  year = {2025},
  doi = {10.1111/nep.14422}
}
Kostenlos starten →